James Ryan is a health economist with over 25 years’ experience across different disease areas, as well as diagnostic technologies, medicines, and devices. He is Director, Global Health Technology Assessment for AstraZeneca representing the company on a regional and international level. He is leading the company’s external engagement and internal work on the upcoming EU HTA, working closely with colleagues across rare diseases, oncology, respiratory and cardiovascular. He is also been supporting EFPIA with their industry response to the EU HTA Regulation, as well as representing AstraZeneca at the HTAi Global Policy Forum.

James has a passion for evidence development across the life cycle and the use of HTA science to demonstrate the comparative benefit and economic value of new health technologies. James has an MSc in Health Economics from the University of York, UK, and has worked in academia, consultancy, and industry over his career.